Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

Lupin Limited has received approval from the United States Food and Drug Administration for its Abbreviated New Drug ...

A multi-ancestry polygenic risk score could help health care professionals predict a person’s risk for developing obesity ...

Investing.com -- Goldman Sachs has initiated coverage on Gubra A/S with a “neutral” rating and a 12-month price target of Dkr520, representing a 23.9% upside from the current price of Dkr419.80, in a ...